XETR
FME
Market cap12bUSD
Jun 18, Last price
41.26EUR
1D
-0.29%
1Q
9.33%
Jan 2017
-48.71%
Name
Fresenius Medical Care AG & Co KGaA
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fresenius Medical Care AG & Co. KGaA, established in Bad Homburg, Germany, in 1996, operates as a global provider of dialysis care and associated services. The company boasts an extensive international footprint, managing 4,171 outpatient dialysis clinics across approximately 150 countries (as of February 23, 2022), with significant operations in Germany and North America. Its comprehensive service portfolio includes in-clinic dialysis treatments, supported by laboratory and diagnostic services, alongside robust home dialysis programs that provide essential materials, training, patient monitoring, and supply delivery. Fresenius Medical Care also contracts with hospitals in the United States to deliver dialysis care to hospitalized patients suffering from acute kidney failure or end-stage renal disease. Beyond core dialysis, the company offers specialized medical services in vascular, cardiovascular, endovascular, nephrology, and cardiology. A key player in medical technology, Fresenius Medical Care actively develops, manufactures, and distributes a broad spectrum of dialysis products. This range encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, hemodialysis concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. They also produce non-dialysis items like acute cardiopulmonary and apheresis products. The firm is additionally involved in the pharmaceutical sector, developing, acquiring, and licensing renal medications and supplies for direct distribution to patients' homes or dialysis clinics. Products are sold to dialysis clinics, hospitals, and specialized treatment centers through direct channels, local sales forces, and a network of independent distributors, dealers, and agents.
IPO date
Oct 02, 1996
Employees
124,295
Domiciled in
DE
Incorporated in
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||